Executive Speak
Organisation Profile
Corporate Governance
DNA of Sustainability
Stakeholder Engagement
Economic Performance
Environment Performance
Social Performance
Talent Management
Product Responsibility
Annexures
 
Economic Performance
Affordable and Innovative Medicine
Overview   |   2009-10 Timeline   |   Global Generics   |   PSAI   |   Proprietary Products
Generic Biopharmaceuticals   |   New Chemical Entities   |   Differentiated Formulations
 
Differentiated Formulations
Our emerging Differentiated Formulations portfolio consists of developing novel formulations of currently marketed drugs or combinations thereof to enhance patient comfort.
We develop synergistic combinations as well as technologies that enhance the drug’s safety and/or efficacy profile by modifying its pharmacokinetics.
Our most advanced Differentiated Formulations efforts are in dermatology, where we have launched several effective and innovative products through Promius PharmaTM.
It is our wholly-owned subsidiary, headquartered at Bridgewater, New Jersey (US) that develops and markets differentiated formulations for important dermatological indications.
   
  Our portfolio includes in-licensed and co-developed dermatological products and an internal pipeline of topical products under development that will provide better answers to the skin care needs of today and tomorrow.
   
Promius Pharma’s current portfolio contains innovative products for the treatment of seborrheic dermatitis, onychomycosis, acne, psoriasis and androgenic alopecia.
The two primary products which address these needs are:
   
 
ScyteraTM Foam is a novel coal tar
foam for the treatment of psoriasis, a
skin disease that affects approximately
7.5 million Americans according to
the National Psoriasis Foundation. ScyteraTM Foam delivers a time
tested active ingredient, coal tar, in a
cosmetically elegant foam formulation.
   
   
 
EpiCeram® Skin Barrier Emulsion is a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million patients in the United States. EpiCeram® was developed to specifically address the defective skin barrier of atopic patients to safely and effectively control the signs and symptoms of atopic dermatitis.
   
has entered into successful partnerships with companies such as Ceragenix, Foamix, Sinclair and Antares for
in-licensing of products.
 
 
<< Previous  |   Next >>
 
       
 
Home  I  Contact Us  I  Report Archive  I  Terms of Use © 2011 Dr. Reddy's Laboratories Ltd.  I  a cognito report